Does the medication pattern reflect the CYP2D6 genotype in patients with diagnoses within the schizophrenic spectrum?

Journal of Clinical Psychopharmacology

Volumn 32, Issue 1, 2012, Pages 100-105

  Jürgens, Gesche ^a   Rasmussen, Henrik B ^b   Werge, Thomas ^b   Dalhoff, Kim ^a   Nordentoft, Merete ^b   Andersen, Stig E ^b  

^a BISPEBJERG HOSPITAL   (Denmark)

^b Mental Health Services CPH   (Denmark)

Author keywords

adverse events; antipsychotics; CYP2D6; medication pattern; schizophrenia; treatment response

Indexed keywords

CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CYTOCHROME P450 2D6; CYTOCHROME P450 INHIBITOR; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CROSS-SECTIONAL STUDY; DRUG METABOLISM; ENZYME METABOLISM; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HOSPITAL PATIENT; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHIZOPHRENIA; TREATMENT RESPONSE;

ADULT; ANTIPSYCHOTIC AGENTS; CHLORPROMAZINE; CROSS-SECTIONAL STUDIES; CYTOCHROME P-450 CYP2D6; DENMARK; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENETIC TESTING; GENOTYPE; HUMANS; MALE; METABOLIC DETOXICATION, DRUG; POLYMORPHISM, GENETIC; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 84855348279     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31823f6b6a     Document Type: Article

References (24)

1. Andersson T, Flockhart DA, Goldstein DB, et al. Drug-metabolizing enzymes: evidence for clinical utility of pharmacogenomic tests. Clin Pharmacol Ther. 2005;78:559-581. (Pubitemid 41773633)
2. Kirchheiner J, Rodriguez-Antona C. Cytochrome P450 2D6 genotyping: potential role in improving treatment outcomes in psychiatric disorders. CNS Drugs. 2009;23:181-191.
3. Fleeman N, McLeod C, Bagust A, et al. The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation. Health Technol Assess. 2010;14:1-157, iii.
4. Bertilsson L, Dahl ML, Dale P, et al. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol. 2002;53:111-122. (Pubitemid 34264265)
5. Kirchheiner J, Seeringer A, Viviani R. Pharmacogenetics in psychiatryVa useful clinical tool or wishful thinking for the future? Curr Pharm Des. 2010;16:136-144.
6. Moore TA, Buchanan RW, Buckley PF, et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry. 2007;68:1751-1762. (Pubitemid 350247505)
7. DRUGDEX\ System [Internet database]. Greenwood Village, CO: Thomson Reuters (Healthcare) Inc. 2010; Accessed August 1, 2010.
8. Flockhardt DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Available at: http://medicine iupui edu/clinpharm/ddis/table asp, 2007. Accessed August 1, 2009.
9. Kirchheiner J, Nickchen K, Bauer M, et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry. 2004;9:442-473. (Pubitemid 38903502)
10. Davis JM. Dose equivalence of the antipsychotic drugs. J Psychiatr Res. 1974;11:65-69.
11. Woods SW, Aakhus AM. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry. 2003;64:663-667. (Pubitemid 36750143)
12. Andreasen NC, Pressler M, Nopoulus P, et al. Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biol Psychiatry. 2010;67:255-262.
13. Kane JM, Leucht S, Carpenter D, et al. The expert consensus guideline series: optimizing pharmacologic treatment of psychotic disorders. J Clin Psychiatry. 2003;64(suppl 12):2-97.
14. Virani AS, Bezchlibnyk-Butler KZ, Jeffries JJ. Clinical Handbook of Psychotropic Drugs. 18 ed. Gö ttingen, Germany: Hogrefe & Huber Publishers; 2009.
15. Hersberger M, Marti-Jaun J, Rentsch K, et al. Rapid detection of the CYP2D6*3, CYP2D6*4, and CYP2D6*6 alleles by tetra-primer PCR and of the CYP2D6*5 allele by multiplex long PCR. Clin Chem. 2000;46:1072-1077. (Pubitemid 30643307)
16. Lovlie R, Daly AK, Molven A, et al. Ultrarapid metabolizers of debrisoquine: characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene. FEBS Lett. 1996;392:30-34. (Pubitemid 26268326)
17. Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics. 2002;3:229-243. (Pubitemid 34223859)
18. Hansen T, Olsen L, Lindow M, et al. Brain expressed microRNAs implicated in schizophrenia etiology. PLoS One. 2007;2:e873.
19. Hansen T, Ingason A, Djurovic S, et al. At-risk variant in TCF7L2 for type II diabetes increases risk of schizophrenia. Biol Psychiatry. 2011;70:59-63.
20. Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl. 1987;334:1-100. (Pubitemid 17115352)
21. Moore TA. Schizophrenia treatment guidelines in the United States. Clin Schizophr Relat Psychoses. 2011;5:15-16.
22. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry. 2004;161:414-425. (Pubitemid 38326094)
23. Barr AM, Honer WG, Johnson JL, et al. A comparison of antipsychotic drug-defined daily doses versus chlorpromazine equivalent doses in patients with or without extrapyramidal motor symptoms. J Clin Psychopharmacol. 2010;30:741-743.
24. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 2005;5:6-13. (Pubitemid 40220611)